Stakeholders push for further pull incentives
With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged for more pull incentives.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
Entries by Thomas Gabrielczyk
Bioversys bags €17.7m financing
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
Sotio licences Unum Therapeutics’ CAR-T cell portfolio
PPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.
Polyphor partners with Fosun Pharma
Polyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China.
Engitix Ltd. lands US$500m deal with Takeda in fibrosis
British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
Moderna set to deliver COVID-19 jab to the EU
US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists map ulcerative colitis
Scientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
COVID-19: Roche and Regeneron join forces
Roche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19.
Aicuris to launch AiCubator to fight AMR
Antinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
Cell-based vaccination vs mortality-reducing therapies
Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.